Related references
Note: Only part of the references are listed.A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
R. A. Sooy et al.
ANNALS OF ONCOLOGY (2022)
When to add anti-angiogenesis drugs to EGFR-mutated metastatic non-small cell lung cancer patients: a real-world study from Taiwan
Chieh-Lung Chen et al.
BMC CANCER (2022)
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study
Hirotsugu Kenmotsu et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
Yen-Hsiang Huang et al.
CANCER RESEARCH AND TREATMENT (2022)
The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis
Tzu-Hsuan Chiu et al.
SCIENTIFIC REPORTS (2022)
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial
Yosuke Kawashima et al.
LANCET RESPIRATORY MEDICINE (2022)
Role of Antiangiogenic Agents Combined With EGFR Tyrosine Kinase Inhibitors in Treatment-naive Lung Cancer: A Meta-Analysis
Zhujun Deng et al.
CLINICAL LUNG CANCER (2021)
Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study
N. Yamamoto et al.
LUNG CANCER (2021)
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial
Hiroaki Akamatsu et al.
JAMA ONCOLOGY (2021)
Non-Small Cell Lung Cancer, Version 2.2021 Featured Updates to the NCCN Guidelines
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model
Chinami Masuda et al.
CLINICAL & EXPERIMENTAL METASTASIS (2020)
Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With AdvancedEGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis
Fei Chen et al.
FRONTIERS IN ONCOLOGY (2020)
First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring anEGFRmutation
Thierry Landre et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Non-small cell lung cancer patients with ex19del or exon 21 L858R mutation: distinct mechanisms, different efficacies to treatments
W. -Q. Li et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial
Thomas E. Stinchcombe et al.
JAMA ONCOLOGY (2019)
EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases
Tao Jiang et al.
EUROPEAN JOURNAL OF CANCER (2019)
Overview of current systemic management of EGFR-mutant NSCLC
W. -H. Hsu et al.
ANNALS OF ONCOLOGY (2018)
Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
Nicolas Girard
FUTURE ONCOLOGY (2018)
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis
Zuyao Yang et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer
Cesare Gridelli et al.
CLINICAL LUNG CANCER (2016)
Bevacizumab plus chemotherapy versus chemotherapy alone for preventing brain metastasis derived from advanced lung cancer
Yan Fu et al.
JOURNAL OF CHEMOTHERAPY (2016)
Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 L858R mutation in non-small-cell lung cancer: Systematic review and meta analysis
Yinghui Liu et al.
THORACIC CANCER (2016)
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis
Chee Khoon Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
Yaxiong Zhang et al.
PLOS ONE (2014)
Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis
Annette K. Larsen et al.
PHARMACOLOGY & THERAPEUTICS (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
The Role of Anti-Epidermal Growth Factor Receptor and Anti-Vascular Endothelial Growth Factor Therapies in the Treatment of Non-Small-Cell Lung Cancer
Corey Langer et al.
CLINICAL LUNG CANCER (2010)
Share Paper
